Department of Psychiatry, Faculty of Medicine, School of Health Sciences, University of Ioannina (UOI), P.O. Box 1186, 45110 Ioannina, Greece.
Department of Psychiatry, Faculty of Medicine, School of Health Sciences, University of Ioannina (UOI), P.O. Box 1186, 45110 Ioannina, Greece.
J Psychosom Res. 2022 Jun;157:110789. doi: 10.1016/j.jpsychores.2022.110789. Epub 2022 Mar 21.
There is increasing evidence that adiponectin, resistin and leptin may be implicated in the pathophysiology of neuropsychiatric disorders, including schizophrenia. The results of the studies so far remain controversial. Our aim was to compare serum adiponectin, leptin and resistin levels between drug-naïve, first -episode patients with psychosis and healthy controls and in the same group of patients after six weeks of antipsychotic treatment.
Forty first-episode patients with psychosis and 40 matched controls were included in the study. Serum levels of adiponectin, resistin and leptin were measured by enzyme linked immunosorbent assay (ELISA) in both groups. In the patient group, the same adipokines were also measured six weeks after the initiation of antipsychotic treatment.
Log-transformed serum levels of adiponectin (mean difference = 1.68, 95% confidence interval [CI] = 1.30 to 2.06, U = 157, p < 0.0001), resistin (0.48, 95% CI = 0.36 to 0.59, t = 8.00, p < 0.0001) and leptin (0.66, 95% CI = 0.52 to 0.80, U = 160, p < 0.0001) were significantly higher to the patient group compared to controls. Leptin levels were significantly decreased in the patient group six weeks after the initiation of antipsychotic treatment (mean change = -0.40, 95% CI = -0.59 to -0.21, W = 666; p < 0.0001) while those of adiponectin and resistin levels did not change significantly.
In our study we found higher levels of adiponectin, leptin and resistin in drug-naïve, first-episode patients with normal Body Mass Index (BMI) compared to controls. After six weeks of antipsychotic treatment, there was no change in adiponectin and resistin levels, while leptin levels were reduced compared to baseline.
越来越多的证据表明脂联素、抵抗素和瘦素可能与神经精神疾病的病理生理学有关，包括精神分裂症。到目前为止，研究结果仍存在争议。我们的目的是比较初发未用药的精神病患者与健康对照组之间以及同一组患者在抗精神病治疗 6 周后血清脂联素、瘦素和抵抗素水平。
本研究纳入了 40 例初发精神病患者和 40 例匹配的对照组。通过酶联免疫吸附试验（ELISA）测量两组血清脂联素、抵抗素和瘦素水平。在患者组中，在开始抗精神病治疗 6 周后还测量了相同的脂肪因子。
经对数转换后，脂联素（平均差异=1.68，95%置信区间[CI]为 1.30 至 2.06，U 值=157，p<0.0001）、抵抗素（0.48，95%CI 为 0.36 至 0.59，t 值=8.00，p<0.0001）和瘦素（0.66，95%CI 为 0.52 至 0.80，U 值=160，p<0.0001）血清水平在患者组中明显高于对照组。在开始抗精神病治疗 6 周后，患者组的瘦素水平显著下降（平均变化=-0.40，95%CI 为-0.59 至-0.21，W 值=666；p<0.0001），而脂联素和抵抗素水平没有明显变化。
在我们的研究中，我们发现初发未用药、BMI 正常的精神病患者的脂联素、瘦素和抵抗素水平高于对照组。在抗精神病治疗 6 周后，脂联素和抵抗素水平没有变化，而瘦素水平与基线相比有所下降。
